Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over safety study of darbepoetin alfa for anemia of cancer without chemotherapy
2004-001154-86Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2004
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer-associated anemia (CRA) comparing Darbepoetin alfa continuation with Placebo (2 arms). Primary endpoint: Incidence of adverse events. Started Aug 2004; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
cancer-associated anemia (CRA)
Beyond the preview
Go deeper on 2004-001154-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001154-86.